Cybin Inc. (CYBN) Launches Global Phase 3 Trial for Breakthrough Depression Therapy
Cybin Inc. (NYSE:CYBN) is a clinical-stage neuropsychiatry company developing psychedelic-based treatments for major depressive disorder (MDD) and generalized anxiety disorder (GAD).



